| Literature DB >> 29324651 |
Małgorzata Kołpa1, Marta Wałaszek2, Agnieszka Gniadek3, Zdzisław Wolak4, Wiesław Dobroś5.
Abstract
Healthcare-associated infections (HAIs) occurring in patients treated in an intensive care unit (ICU) are serious complications in the treatment process. Aetiological factors of these infections can have an impact on treatment effects, treatment duration and mortality. The aim of the study was to determine the prevalence and microbiological profile of HAIs in patients hospitalized in an ICU over a span of 10 years. The active surveillance method was used to detect HAIs in adult patients who spent over 48 h in a general ICU ward located in southern Poland between 2007 and 2016. The study was conducted in compliance with the methodology recommended by the Healthcare-associated Infections Surveillance Network (HAI-Net) of the European Centre for Disease Prevention and Control (ECDC). During the 10 years of the study, 1849 patients hospitalized in an ICU for a total of 17,599 days acquired 510 with overall HAIs rates of 27.6% and 29.0% infections per 1000 ICU days. Intubation-associated pneumonia (IAP) posed the greatest risk (15.2 per 1000 ventilator days), followed by CLA-BSI (8.0 per 1000 catheter days) and CA-UTI (3.0 per 1000 catheter days). The most common isolated microorganism was Acinetobacter baumannii (25%) followed by Coagulaase-negativ staphylococci (15%), Escherichia coli (9%), Pseudomonas aeruginosa (8%), Klebsiella pneumoniae (7%), Candida albicans (6%). Acinetobacter baumannii in 87% and were classified as extensive-drug resistant (XDR). In summary, in ICU patients pneumonia and bloodstream infections were the most frequently found. Acinetobacter baumannii strains were most often isolated from clinical materials taken from HAI patients and showed resistance to many groups of antibiotics. A trend of increasing resistance of Acinetobacter baumannii to carbapenems was observed.Entities:
Keywords: Acinetobacter baumannii; antibiotic resistance; bloodstream infection urinary tract infection; healthcare-associated infections; hospital infection intensive care unit; ventilator-associated pneumonia
Mesh:
Year: 2018 PMID: 29324651 PMCID: PMC5800211 DOI: 10.3390/ijerph15010112
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Number of HAIs/100 admissions (%), number of HAIs/1000 person days (n/1000), person days (n) by major and specific sites of infection in an intensive care unit in the years 2007–2016.
| HAI Types | Incidence (%) per 100 Admissions to ICU | Incidence Density per 1000 Days in ICU | Number of Person Days with Invasive Device * | Incidence Density per 1000 Person Days with Device | DUR | |
|---|---|---|---|---|---|---|
| All HAIs | 510 | 27.6 | 29.0 | |||
| PN1: minimally contaminated LRT sample with quantitative culture | 13 | 0.7 | 0.7 | 12,059 | 15.2 * | 0.65 |
| PN2: non-protected sample with quantitative culture | 14 | 0.8 | 0.8 | |||
| PN3: alternative microbiological criteria | 6 | 0.3 | 0.3 | |||
| PN4: sputum bacteriology or non-quantitative | 145 | 7.9 | 8.2 | |||
| PN5: no microbiological documentation | 5 | 0.3 | 0.3 | |||
| BSI-C: Primary BSI catheter-related | 24 | 1.3 | 1.4 | 17,858 | 8.0 ** | 0.96 |
| BSI-UO: Primary BSI of unknown origin | 118 | 6.4 | 6.7 | |||
| BSI-S: secondary BSI | 17 | 0.9 | 1.0 | n/a | n/a | n/a |
| UTI-A: microbiologically confirmed symptomatic | 54 | 2.9 | 3.1 | 18,192 | 3.0 *** | 0.98 |
| UTI-B: not microbiologically confirmed symptomatic | 0 | 0,0 | 0.0 | |||
| GI-CDI: clostridium difficile infection | 20 | 1.1 | 1.1 | n/a | n/a | n/a |
| GI-GE: gastroenteritis | 18 | 1.0 | 1.0 | n/a | n/a | n/a |
| SSI-D: Deep incisional | 18 | 1.0 | 1.0 | n/a | n/a | n/a |
| SSI-O: Organ/space | 6 | 0.3 | 0.3 | n/a | n/a | n/a |
| SSI-S: Superficial incisional | 9 | 0.5 | 0.5 | n/a | n/a | n/a |
| SST-DECU: soft tissue | 17 | 0.9 | 1.0 | n/a | n/a | n/a |
| SST-SKIN: skin infection | 5 | 0.3 | 0.3 | n/a | n/a | n/a |
| SST-ST: soft tissue | 3 | 0.2 | 0.2 | n/a | n/a | n/a |
Number of patients in ICU = 1847; the number of days in ICU = 17,599, HAI: hospital acquired infections; N: number; * per 1000 ventilator days; ** per 1000 central line days; *** per 1000 catheter days; n/a: not applicable; LRT: lower respiratory tract, device use ratio (DUR).
HAI risk factors in the ICU, 2007–2016.
| Risk Factor | Patients without HAI | HAI Patients | Total | OR (95% CI) | Pearson’s Correlation | |
|---|---|---|---|---|---|---|
| Central catheter | 885 (72.5%) | 335 (27.9%) | 1220 (100%) | 1.0 (0.8–1.2) | 0.869 | 0.0 |
| Arterial catheter | 443 (71.0%) | 181 (29.0%) | 624 (100%) | 1.1 (0.9–1.4) | 0.595 | 0.0 |
| Intubation | 287 (86.2%) | 134 (31.8%) | 421 (100%) | 1.3 (1.0–1.7) | 0.265 | 0.1 |
| Mechanical ventilation | 887 (69.8%) | 383 (30.2%) | 1270 (100%) | 1.5 (1.2–1.9) | <0.05 | 0.1 |
| Urethral catheter | 259 (65.9%) | 134 (34.1%) | 393 (100%) | 1.5 (1.2–1.9) | <0.001 | 0.1 |
| Stomach probe | 447 (71.0%) | 183 (29.0%) | 630 (100%) | 1.1 (0.9–1.4) | 0.884 | 0.0 |
| Blood | 310 (53.0%) | 275 (47.0%) | 585 (100%) | 3.9 (3.1–4.8) | <0.001 | 0.3 |
| Pleural drainage | 67 (46.5%) | 77 (53.5%) | 144 (100%) | 3.4 (2.4–4.8) | <0.001 | 0.2 |
| Tracheostomy | 98 (27.9%) | 253 (72.1%) | 351 (100%) | 12.4 (9.5–16.3) | <0.001 | 0.5 |
| Peg | 38 (30.6%) | 86 (69.4%) | 124 (100%) | 6.9 (4.7–10.3) | <0.001 | 0.3 |
| Plasma | 196 (54.0%) | 167 (46.0%) | 363 (100%) | 2.8 (2.2–3.6) | <0.001 | 0.2 |
| Bronchoscopy | 117 (39.1%) | 182 (60.9%) | 299 (100%) | 5.8 (4.5–7.5) | <0.001 | 0.3 |
| Parenteral nutrition | 101 (57.4%) | 75 (42.6%) | 176 (100%) | 2.1 (1.5–2.9) | <0.001 | 0.1 |
| Gastroscopy | 37 (26.4%) | 103 (73.6%) | 140 (100%) | 8.9 (6.0–13.2) | <0.001 | 0.3 |
Chi-square (p); Odds ratio (OR); 95% confidence interval (CI); percutaneous endoscopic gastrostomy (PEG).
Microorganisms isolated in HAI in the ICU, 2007–2016.
| Number of HAI with Microorganisms, All | BSI | PN | UTI | SSI | GI | SST | OTH | |
|---|---|---|---|---|---|---|---|---|
| 156 | 174 | 54 | 32 | 27 | 25 | 18 | ||
| Coagulase-negative staphylococci (%) | 70 | 69 (44.2) | 1 (5.6) | |||||
| 33 | 10 (6.4) | 16 (9.2) | 2 (6.3) | 2 (8.0) | 3 (16.6) | |||
| 32 | 2 (1.1) | |||||||
| 3 | 3 (1.7) | |||||||
| 19 | 19 (70.4) | |||||||
| 44 | 8 (5.1) | 16 (9.2) | 10 (18.5) | 4 (12.5) | 5 (20.0) | 1 (5.6) | ||
| 35 | 8 (5.1) | 14 (8.0) | 2 (3.7) | 1 (3.1) | 5 (20.0) | 7 (17.9) | ||
| 18 | 4 (2.6) | 7 (4.0) | 4 (7.4) | 1 (3.1) | 2 (8.0) | |||
| 11 | 7 (4.0) | 2 (3.7) | 1 (3.1) | 1 (4.0) | ||||
| 5 | 3 (1.9) | 1 (0.6) | 1 (3.1) | |||||
| 4 | 1 (0.6) | 1 (0.6) | 2 (3.70) | |||||
| 120 | 27 (17.3) | 72 (41.4) | 4 (7.4) | 8 (25.0) | 4 (16.0) | 5 (27.7) | ||
| 39 | 5 (3.2) | 20 (11.5) | 6 (11.1) | 5 (15.6) | 1 (4.0) | 2 (11.1) | ||
| 3 | 1 (0.6) | 1 (0.6) | 1 (4.0) | |||||
| 2 | 2 (1.1) | |||||||
| 1 | 1 (0.6) | |||||||
| Other bacteria (%) | 9 | 3 (1.9) | 3 (1.7) | 2 (6.3) | 1 (4.0) | |||
| 28 | 6 (3.8) | 5 (2.9) | 11 (20.4) | 1 (3.1) | 5 (18.5) | |||
| 2 | 2 (6.3) | |||||||
| 1 | ||||||||
| Adenovirus | 1 | 1 (3.7) | ||||||
| Norovirus | 1 | 1 (3.7) |
N: number; pneumonia (PN); blood stream infections (BSI); urinary tract infection (UTI); Gastrointestinal (GE); Surgical site infection (SSI); skin and soft tissue infection (SST); Other infections (OTH).
Days until HAI onset, ICU length of stay, mortality related to the microorganism that gave rise to HAI in the ICU in the years 2007–2016.
| Infection Types | Average Number of Days between Admission to HAI Emergence | Average Number of Days of Patient’s Stay in ICU | |||
|---|---|---|---|---|---|
| Pooled Mean (95% CI) | SD | Pooled Mean (95% CI) | SD | ||
| type HAI | |||||
| Patients without HAI | 1337 | n/a | n/a | 19.0 (17.9–20.1) | 21.1 |
| Pneumonia | 183 | 19.2 (16.7–21.7) | 17.3 | 51.5 (45.8–57.2) | 39.0 |
| Blood stream infections | 159 | 24.1 (20.2–27.9) | 24.7 | 49.2 (42.9–55.6) | 39.7 |
| Urinary tract infection | 54 | 30.4 (23.9–36.8) | 23.6 | 62.3 (50.9–73.6) | 41.2 |
| Gastrointestinal | 38 | 13.7 (11.2–16.3) | 7.7 | 42.2 (29.8–55.0) | 37.8 |
| Surgical site infection | 33 | 26.3 (21.4–31.2) | 13.8 | 67.0 (50.7–83.3) | 45.9 |
| Skin and soft tissue infection | 25 | 42.0 (29.2–54.8) | 31.1 | 73.2 (55.7–90.6) | 41.3 |
| Other infections | 18 | 14.3 (7.5–21.1) | 13.7 | 34.5 (23.6–51.6) | 28.2 |
| Total | 1847 | 22.9 (21.0024.8) | 21.0 | 28.2 (26.8–29.7) | 31.5 |
| Materiality ANOVA ( | n/a | n/a | n/a | ||
| selected aetiological HAI factors | |||||
| 19 | 12.4 (8.4–16.4) | 8.3 | 35.5 (19.2–51.8) | 32.7 | |
| 33 | 19.0 (16.1–22.0) | 16.2 | 50.3 (33.4–80.6) | 40.8 | |
| 70 | 20.8 (16.4–32.5) | 28.5 | 47.5 (35.7–58.5) | 39.5 | |
| 18 | 22.7 (15.6–23.1) | 15.7 | 58.3 (42.0–71.9) | 43.3 | |
| 120 | 23.6 (17.6–29.6) | 19.7 | 40.0 (37.2–51.0) | 22.7 | |
| 44 | 24.3 (18.0–29.0) | 15.3 | 53.7 (46.3–61.1) | 40.6 | |
| 35 | 27.1 (13.2–37.5) | 25.3 | 67.8 (46.4–77.8) | 45.1 | |
| 28 | 31.5 (23.0–39.9) | 26.2 | 57.5 (45.9–69.1) | 38.3 | |
| 39 | 35.9 (24.4–44.4) | 29.7 | 59.7 (42.3–73.5) | 42.8 | |
| 32 | 36.2 (25.5–45.6) | 30.2 | 66.3 (52.3–80.2) | 43.1 | |
N: number; Me: median; SD: standard deviation; 95% confidence interval (CI) for mean; n/a: not applicable; CNS: coagulase-negative staphylococci.
Antimicrobial resistance in HAI in the ICU, 2007–2016.
| Microbial Genus/Species | Number of Isolates, Total | Number of Isolates with Resistance Mechanism | Resistant Codes | |
|---|---|---|---|---|
| Gram-positive cocci | ||||
| 33 | 10 (30.3) | MRSA | 7 (21.1) | |
| MLSB | 3 (9.1) | |||
| Coagulase-negative staphylococci (%) | 70 | 30 (42.8) | MRSA | 25 (35.7) |
| MLSB | 5 (7.1) | |||
| 32 | 10 (31.2) | HLAR | 10 (31.2) | |
| Enterobacteriaceae | ||||
| 44 | 3 (6.8) | ESBL | 3 (6.8) | |
| 35 | 10 (28.6) | MBL | 2 (5.7) | |
| ESBL | 8 (22.9) | |||
| Non-fermenting gram-negative bacteria | ||||
| 120 | 5 (4.1) | MBL | 5 (4.1) | |
| 18 | 3 (16.6) | ESBL | 3 (16.6) | |
MRSA: methicillin-resistant Staphylococcus aureus; ESBL: extended beta-lactamase produced; HLAR: high-level aminoglycoside resistance; MBL: metalo-beta lactamase.
Resistance to a selected group of antibiotics and type of multi-drug resistance in the ICU in the years 2007–2016.
| Antibiotic Name | |||
|---|---|---|---|
| Aminoglycosides (%) | |||
| Gentamicin | 63.7 | 25.0 | 25.0 |
| Tobramycin | 81.1 | 10.0 | 33.3 |
| Amikacin | 95.6 | 15.0 | 25.0 |
| Netilmicin | 88.4 | 20.0 | 16.6 |
| Antipseudomonal carbapenems (%) | |||
| Imipenem | 30.4 | 35.0 | 0.0 |
| Mero penem | 33.3 | 20.0 | 8.3 |
| Extended-spectrum cephalosporins (%) | |||
| Ceftazidime | 98.1 | 15.0 | 41.6 |
| Cefepime | 94.5 | 25.0 | 16.6 |
| Cefotaxime | 99.3 | 75.0 | 58.3 |
| Ceftriaxone | 97.8 | 65.7 | 66.6 |
| Antipseudomonal fluoroquinolones (%) | |||
| Ciprofloxacin | 97.8 | 10.0 | 41.6 |
| Levofloxacin | 95.6 | 10.0 | 8.3 |
| Penicillins (piperacillin) (%) | |||
| Piperacillin | 0.0 | 20.0 | 0.0 |
| Penicillins and b-lactamase inhibitors (%) | |||
| Ticarcillin clavulanic acid | 0.0 | 20.0 | 16.6 |
| Piperacillin tazobactam | 98.7 | 0.5 | 25.0 |
| Ampicillin Sulbactam | 57.8 | 0.0 | 0.0 |
| Cephalosporins and inhibitors (%) | |||
| Cefoperazone sulbactam | 11.5 | 15.0 | 16.6 |
| Polymyxins (%) | |||
| Colistin | 1.2 | 0.5 | 0.0 |
| Polymyxin B | 0.0 | 0.0 | 0.0 |
| Type of resistance | |||
| Sensitive (%) | 1.4 | 65.0 | 58.3 |
| MDR (%) | 11.5 | 30.0 | 16.6 |
| XDR (%) | 86.9 | 0.0 | 25.0 |
| PDR (%) | 0.0 | 0.0 | 0.0 |
Compilation of the number of Acinetobacter baumannii isolates resistant to carbapenems in the years 2007–2016.
| Year | Number of | Imipenem | Meropenem |
|---|---|---|---|
| 2007 | 11 | 1 (9.1) | 0 (0.0) |
| 2008 | 26 | 2 (7.7) | 1 (3.8) |
| 2009 | 26 | 3 (11.5) | 2 (7.7) |
| 2010 | 7 | 1 (14.4) | 4 (57.1) |
| 2011 | 3 | 1 (33.3) | 1 (33.3) |
| 2012 | 13 | 6 (46.2) | 9 (69.2) |
| 2013 | 4 | 1 (25.0) | 3 (75.0) |
| 2014 | 11 | 7 (63.6) | 7 (63.6) |
| 2015 | 13 | 10 (76.9) | 10 (76.9) |
| 2016 | 6 | 4 (66.7) | 3 (50.0) |
| totality | 120 | 36 (30.4) | 40 (33.3) |
n (%): number and percentage of strains resistant to imipenem and meropenem.